Zyuds Lifesciences receives USFDA approval for Duchenne Muscular Dystrophy treatment drug

Zydus Lifesciences on Friday, April 11, announced that it received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) tablets.

“Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older,” the pharma company said.

The drug maker will produce Jaythari (Deflazacort) 6 mg, 18 mg, 30 mg and 36 mg tablets at Doppel Farmaceutici S.r.l., Italy facility, Zydus said in a regulatory filing.

The company has 424 approvals and has so far filed 492 Abbreviated New Drug Applications (ANDAs) as of March 31, 2025.

Zydus incorporates a wholly owned subsidiary in France

Zydus Lifesciences also informed the exchanges that it has incorporated a step-down subsidiary Zydus MedTech (France) SAS, via its wholly owned subsidiary Zydus MedTech Private Ltd.

On March 11, the drug maker announced that it acquired a majority stake of 85.6% equity shares in Amplitude Surgical SA, France for 256.8 million euros.

Zydus will transfer the equity shares of Amplitude Surgical SA to the newly incorporated Zydus MedTech (France) SAS, the regulatory filing stated.

Zydus share reaction

Shares of Zydus Lifesciences closed at ₹868.85 apiece, up 2.90% on the National Stock Exchange (NSE) on Friday.

The stock gained 0.22% over the week but lost 1.98% since the beginning of April. The scrip has declined 10.58% on a year-to-date basis.

Zydus Lifesciences has a total market capitalisation of ₹87,265.64 crore, as of April 12, 2025, on the NSE.